Lymphoma & Plasma Cell Disorders
Conference Coverage
FLYER: Four cycles of R-CHOP as good as six in low-risk DLBCL
SAN DIEGO – Survival outcomes were nearly identical and adverse events were lower with four versus six cycles of R-CHOP in patients with favorable...
Video
FLYER: R-CHOP 4 safer, as effective for low-risk DLBCL patients under 60
SAN DIEGO – Progression-free, event-free, and overall survival were comparable with that of patients assigned to six cycles of therapy.
From the Journals
New data further support curability of myeloma
A study has found that a sizable share of transplant-eligible patients can expect to live as long as similar people in the general population.
News
FDA approves biosimilar rituximab for NHL
The U.S.
News
FDA approves rituximab biosimilar for lymphoma
Truxima is the first biosimilar approved in the United States to treat non-Hodgkin lymphoma.
From the Journals
Cortactin expression aids in CLL-MCL differential
Cortactin, a cytoskeleton-remodeling adapter protein, is expressed on most CLL cells, but not similar-appearing MCL cells.
News
EC approves mogamulizumab for MF, SS
The European Commission (EC) has granted marketing authorization for mogamulizumab (Poteligeo), a humanized monoclonal antibody directed against...
News
Pegfilgrastim biosimilar approved by EC
The European Commission (EC) has granted marketing authorization for Sandoz’s pegfilgrastim product Ziextenzo®, a biosimilar of Amgen’s Neulasta...
Original Report
Patterns of malignancies in patients with HIV-AIDS: a single institution observational study
News
EC approves pegfilgrastim biosimilar
The European Commission (EC) has approved Mundipharma’s pegfilgrastim product Pelmeg, a biosimilar of Amgen’s Neulasta. Pelmeg is approved for...